MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-07-2022
Concert Pharmaceuticals ROA Ratio 2011-2026 | CNCE
Annual ROA Ratio Concert Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -48.42 | -46.94 | -56.86 | -29.1 | 45.17 | -50.52 | 16.45 | -37.53 | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 45.17 | -56.86 | -25.97 |
Quarterly ROA Ratio Concert Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -75.2 | -96.01 | -70.77 | -67.12 | -33.35 | -47.41 | -38.48 | -50.28 | -46.94 | -47.79 | -48.42 | -53.84 | -56.86 | -52.79 | -49.31 | -42.66 | -29.1 | -21.13 | 48.38 | 49.15 | 45.17 | 36.04 | -35.76 | -42.99 | -50.52 | -38.06 | -32.57 | 8.75 | 16.45 | 5.42 | 1.96 | -35.43 | -37.53 | -41.84 | -50.48 | -18.98 | -15.23 | -0.35 | 17.56 | -4.47 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 49.15 | -96.01 | -27.57 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M |  USA |
 |
Ocular Therapeutix
OCUL
|
-32.91 | $ 7.85 | -2.73 % | $ 1.47 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.02 | $ 19.59 | 0.31 % | $ 916 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-78.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Pfizer
PFE
|
3.73 | $ 27.4 | -0.63 % | $ 156 B | USA |
 |
Precigen
PGEN
|
-161.18 | $ 3.83 | -1.79 % | $ 1.2 B | USA |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.22 | -5.81 % | $ 311 M | Britain |
 |
ProQR Therapeutics N.V.
PRQR
|
-29.43 | $ 1.47 | -2.04 % | $ 99.5 M |  Niderland |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
PTC Therapeutics
PTCT
|
23.55 | $ 66.68 | -0.48 % | $ 5.3 B | USA |
 |
RedHill Biopharma Ltd.
RDHL
|
-53.95 | $ 0.8 | 1.48 % | $ 428 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-94.17 | - | -3.03 % | $ 260 M | USA |
 |
Dr. Reddy's Laboratories Limited
RDY
|
6.49 | $ 13.61 | -1.16 % | $ 2.26 B |  India |
 |
Regeneron Pharmaceuticals
REGN
|
11.11 | $ 750.41 | -0.84 % | $ 78.5 B | USA |
 |
ChemoCentryx
CCXI
|
-30.95 | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-54.23 | $ 1.08 | -0.92 % | $ 22.2 M | Israel |
 |
Enochian Biosciences
ENOB
|
-2162.69 | - | - | $ 40.5 M | USA |
 |
REGENXBIO
RGNX
|
-42.8 | $ 7.98 | -3.39 % | $ 412 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Rigel Pharmaceuticals
RIGL
|
71.46 | $ 26.1 | -1.02 % | $ 469 M | USA |
 |
Relay Therapeutics
RLAY
|
-38.76 | $ 9.68 | -4.35 % | $ 1.38 B | USA |